Navigation Links
NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
Date:4/22/2009

ce, they have published successful results of a Phase II clinical trial in ear infections (otitis externa) using NCT. NovaBay expects Alcon, its licensee for the use of Aganocide compounds in the treatment of eye, ear, and sinus infections, to start human trials in the ear during 2009 with NovaBay's lead Aganocide compound NVC-422. Professors Nagl and Gottardi have also pursued studies with NCT in additional indications that can provide NovaBay with guidance in its future clinical programs.

In addition to the research agreement, NovaBay has obtained an exclusive license to a broad portfolio of intellectual property covering uses of NCT compounds. As a result, NovaBay has augmented its composition of matter patent for Aganocide compounds with a license to a series of patents covering key potential uses, including utility of NCT compounds in pulmonary diseases and their potential use in major animal health markets, such as mastititis.

"We are very excited to collaborate with this world-class research team, and pleased to draw on the extensive experience of Professors Gottardi and Nagl in understanding the role of our class of molecules in the prevention and treatment of infectious diseases," said Dr. Ron Najafi, Chairman and Chief Executive Officer of NovaBay. "We look forward to building on their work to further expand the range of clinical opportunities provided by our Aganocide compound platform."

"We expect to substantially broaden NovaBay's efforts by leveraging the resources and expertise at the Medical University of Innsbruck," said Dr. Bez Khosrovi, Vice President of Research and Development at NovaBay. "We see this collaboration as adding significant depth to our preclinical and clinical development programs and to the continued exploration of the properties of our Aganocide compounds. We expect that our joint efforts will provide important information that may further accelerate our efforts to develop
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... May 28, 2015  Eli Lilly and Company (NYSE: ... announced cash tender offer for up to $1.6 billion aggregate ... Holders of notes who tendered, and did not validly ... New York City time, on May 27, 2015 ... by Lilly, are eligible to receive the total consideration. The ...
(Date:5/28/2015)... 28, 2015  Maetrics ( http://maetrics.com ), a leading ... wrapped up a successful conference, "The cost of non-compliance -- ... today in Zurich . ... its Switzerland -based team, experts provided ... Technology field to an exclusive local audience. The event ...
(Date:5/28/2015)... -- This report analyzes the worldwide markets for Intraocular Lenses ... Standard Intraocular Lenses, and Premium Intraocular Lenses. The report provides ... , Japan , Europe ... , and Rest of World. Annual estimates and forecasts ... seven-year historic analysis is provided for these markets. Market data ...
Breaking Medicine Technology:Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Maetrics Hosts Innovative Medical Cluster Event in Switzerland 2World Intraocular Lenses Industry 2World Intraocular Lenses Industry 3World Intraocular Lenses Industry 4World Intraocular Lenses Industry 5World Intraocular Lenses Industry 6World Intraocular Lenses Industry 7World Intraocular Lenses Industry 8World Intraocular Lenses Industry 9World Intraocular Lenses Industry 10World Intraocular Lenses Industry 11World Intraocular Lenses Industry 12World Intraocular Lenses Industry 13World Intraocular Lenses Industry 14World Intraocular Lenses Industry 15World Intraocular Lenses Industry 16World Intraocular Lenses Industry 17World Intraocular Lenses Industry 18World Intraocular Lenses Industry 19World Intraocular Lenses Industry 20World Intraocular Lenses Industry 21World Intraocular Lenses Industry 22World Intraocular Lenses Industry 23World Intraocular Lenses Industry 24World Intraocular Lenses Industry 25World Intraocular Lenses Industry 26
... Lexicon Pharmaceuticals, Inc. (Nasdaq: ... treatments for human disease, announced data from a recently ... oral dose formulation for LX4211, a dual inhibitor of ... Results from the study demonstrated that administration of ...
... Jan. 5, 2011 The pharmaceutical industry,s steep ... strategy and development executives to uncover opportunities for ... combination therapies with branded products to extend patent ... products can extend a therapeutic advantage and become ...
Cached Medicine Technology:Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients 2Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients 3Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients 4Report Highlights Successful Strategies for Bringing FDC Products to Market 2
(Date:5/29/2015)... RIDGELAND, Miss. (PRWEB) May 29, 2015 ... recently announced the graduates of its Advanced Training ... trains students, who fill roles in their health ... both the theory and methodology of continuous quality ... is a sister-program to Dr. Brent James’ internationally ...
(Date:5/29/2015)... Intermountain Healthcare of Salt ... Stratus Video Interpreting for on-demand medical ... and timely care for patients with limited ... video remote interpreting (VRI) services will supplement ... quickly access qualified medical interpretation in nearly ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Mediaplanet has ... to educate readers on the importance of proper sun ... within USA Today, with a circulation of approximately 250,000 ... digital component is distributed nationally, through a vast social ... sites and partner outlets. To explore the digital version ...
(Date:5/29/2015)... OncLive proudly announces the 2015 Giants of ... a panel of eminent oncologists for landmark achievements that ... be introduced and celebrated TONIGHT at the 3rd Annual ... CDT at The Chicago Illuminating Company, 2110 S. Wabash ... groundbreaking accomplishments, in fields including translational research, gene therapy, ...
(Date:5/29/2015)... TX (PRWEB) May 29, 2015 ... 2015” provides comprehensive information on the therapeutic development ... types of muscles in the body, leading to ... R&D pipelines by identifying new targets and MOAs ... on H1 2015 pipeline review of Axillary Hyperhidrosis ...
Breaking Medicine News(10 mins):Health News:HORNE LLP’s Healthcare Delivery Institute Graduates Class from the Advanced Training Program 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 3Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 4Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 2Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 3Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 4Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4
... CNN, MSNBC, Bloomberg and FOX News ... ... MedeFile,International, Inc. (OTC Bulletin Board: MDFI), a company specializing in,portable ... a nationally televised advertising campaign to,generate broad consumer awareness of ...
... Kalanchoe fedtschenkoi, is unique because, unlike normal plants, it captures ... is cooler and more humid, making it 10 times more ... use the latest next-generation DNA sequencing to analyse the plant,s ... , The project will generate a genome sequence database ...
... Lags Specialists, IRVING, Texas, June 19 ... on average than are family,physicians, according to a ... largest physician recruiting firm., The firm,s 2008 ... the average salary offered to recruit family physicians ...
... efforts key to Blue companies, stewardship of,healthcare dollars, ... Blue,Shield companies, anti-fraud investigations resulted in overall savings ... according to data released,by the Blue Cross and ... result for all Blue Cross and Blue Shield ...
... Automate and Connect 80 Physicians, CHICAGO ... leading provider of clinical software, connectivity and ... today announced that,Martin Memorial Health Systems (MMHS) ... and Practice Management (PM) solution to,automate clinical ...
... China, June 19 /Xinhua-PRNewswire/ -- WuXi PharmaTech,(Cayman) Inc. ... and,medical device research and development outsourcing company with ... that it has posted its 2007,annual report on ... http://www.wuxipharmatech.com ., (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ...
Cached Medicine News:Health News:MedeFile Launches National Televised Ad Campaign 2Health News:MedeFile Launches National Televised Ad Campaign 3Health News:MedeFile Launches National Televised Ad Campaign 4Health News:Report: Some Nurses Paid More Than Family Physicians 2Health News:Report: Some Nurses Paid More Than Family Physicians 3Health News:Blue Cross and Blue Shield Companies' Anti-Fraud Units Recover and Save More Than $249 Million In 2007 2Health News:Blue Cross and Blue Shield Companies' Anti-Fraud Units Recover and Save More Than $249 Million In 2007 3Health News:Martin Memorial Health Systems Selects Allscripts for Electronic Health Record and Practice Management 2Health News:Martin Memorial Health Systems Selects Allscripts for Electronic Health Record and Practice Management 3Health News:Martin Memorial Health Systems Selects Allscripts for Electronic Health Record and Practice Management 4Health News:WuXi PharmaTech 2007 Annual Report Available Online 2
2.0mm Rounded Tip, 12mm From Tip to Bend Gently Curved, 15mm Shaft; In Titanium...
Double ended with 0.5mm x 10mm and 1.0mm x 15mm blades; both blades gently curved; round serrated handle, In Titanium....
0.6mm Tip x10mm Shaft, Straight Shaft, 90 Degree Hook at Tip; overall length 120mm; in Titianium....
... The SURPASS Perfusion Catheter is ... the stenotic portion of a ... stenosis for the purpose of ... Perfusion Catheters are also designed ...
Medicine Products: